Christian Medical College and Hospital, Christian Medical College Vellore, Vellore, Tamil Nadu, India.
J Nephrol. 2023 Apr;36(3):695-704. doi: 10.1007/s40620-022-01534-3. Epub 2023 Feb 21.
Biomarkers are fundamental tools for differentiating between types of acute kidney injury (AKI) and may thus be crucial in management and prognosis. We report on a recently described biomarker, calprotectin, that appears to be a promising candidate in differentiating hypovolemic/functional AKI from intrinsic/structural AKI, whose acknowledgement may play a role in improving outcomes. We aimed to study the efficacy of urinary calprotectin in differentiating these two forms of AKI. The effect of fluid administration on the subsequent clinical course of AKI, its severity and the outcomes were also studied.
Children who presented with conditions predisposing to AKI or with diagnosis of AKI were included. Urine samples for calprotectin analysis were collected and stored at - 20 ºC for analysis at the end of the study. Fluids were administered as per clinical conditions, followed by intravenous furosemide 1 mg/kg, and patients were observed closely for at least 72 h. Children with serum creatinine normalization and clinical improvement were classified as with functional AKI, while those with no response were classified as with structural AKI. Urine calprotectin levels between these two groups were compared. Statistical analysis was performed with SPSS 21.0 software.
Of the 56 children enrolled, 26 were classified as with functional AKI and 30 as with structural AKI. Stage 3 AKI was observed in 48.2% of patients and stage 2 AKI in 33.8%. Mean urine output, creatinine and stage of AKI improved with fluid and furosemide or furosemide alone (OR 6.08, 95% CI 1.65-27.23) (p < 0.01). A positive response to fluid challenge was in favor of functional AKI (OR 6.08, 95% CI 1.65-27.23) (p = 0.008). Presence of edema, sepsis and need for dialysis were hallmarks of structural AKI (p < 0.05). Urine calprotectin/creatinine values were 6 times higher in structural AKI compared to functional AKI. Urine calprotectin/creatinine ratio showed the best sensitivity (63.3%) and specificity (80.7%) at a cut-off value of 1 mcg/mL in differentiating the two types of AKI.
Urinary calprotectin is a promising biomarker that may help differentiating structural from functional AKI in children.
生物标志物是区分急性肾损伤 (AKI) 类型的基本工具,因此在管理和预后方面可能至关重要。我们报告了一种最近描述的生物标志物——钙卫蛋白,它似乎是区分低血容量/功能性 AKI 与内在/结构性 AKI 的有前途的候选物,其认识可能有助于改善结局。我们旨在研究尿钙卫蛋白在区分这两种类型 AKI 中的功效。还研究了液体管理对 AKI 后续临床病程、严重程度和结局的影响。
纳入有发生 AKI 倾向的条件或 AKI 诊断的儿童。收集尿液样本进行钙卫蛋白分析,并在研究结束时储存在-20°C 下进行分析。根据临床情况给予液体,然后给予静脉注射呋塞米 1mg/kg,并密切观察患者至少 72 小时。血清肌酐正常化和临床改善的患者被归类为功能性 AKI,而无反应的患者被归类为结构性 AKI。比较这两组之间的尿钙卫蛋白水平。使用 SPSS 21.0 软件进行统计分析。
在纳入的 56 名儿童中,26 名被归类为功能性 AKI,30 名被归类为结构性 AKI。患者中有 48.2%存在 3 期 AKI,33.8%存在 2 期 AKI。液体和呋塞米或呋塞米单独使用后,平均尿量、肌酐和 AKI 分期均有所改善(OR 6.08,95%CI 1.65-27.23)(p<0.01)。液体挑战的阳性反应有利于功能性 AKI(OR 6.08,95%CI 1.65-27.23)(p=0.008)。存在水肿、败血症和需要透析是结构性 AKI 的特征(p<0.05)。结构性 AKI 患者的尿钙卫蛋白/肌酐值比功能性 AKI 高 6 倍。尿钙卫蛋白/肌酐比值在 1 mcg/mL 截断值时具有最佳的敏感性(63.3%)和特异性(80.7%),可区分两种类型的 AKI。
尿钙卫蛋白是一种有前途的生物标志物,可帮助区分儿童的结构性和功能性 AKI。